Eli Lilly and (LLY) Sets New 1-Year Low at $75.50
Eli Lilly and Co (NYSE:LLY) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $75.50 and last traded at $76.18, with a volume of 4498367 shares traded. The stock had previously closed at $76.72.
Several research analysts have recently issued reports on LLY shares. Barclays boosted their price objective on shares of Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, October 13th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Friday, October 13th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Monday, October 16th. Leerink Swann boosted their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Finally, Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $92.02.
The stock has a market capitalization of $81,710.00, a PE ratio of -371.05, a P/E/G ratio of 1.43 and a beta of 0.23. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 3.03%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is currently -1,040.00%.
In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares in the company, valued at $334,901.70. The disclosure for this sale can be found here. Insiders sold 261,613 shares of company stock worth $22,894,997 over the last 90 days. 0.20% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Beach Investment Management LLC. bought a new stake in Eli Lilly and in the second quarter valued at approximately $400,000. LMR Partners LLP bought a new stake in Eli Lilly and in the second quarter valued at approximately $1,672,000. Dowling & Yahnke LLC increased its stake in Eli Lilly and by 0.9% in the second quarter. Dowling & Yahnke LLC now owns 61,575 shares of the company’s stock valued at $5,068,000 after purchasing an additional 544 shares in the last quarter. State of Wisconsin Investment Board increased its stake in Eli Lilly and by 16.5% in the second quarter. State of Wisconsin Investment Board now owns 1,046,784 shares of the company’s stock valued at $86,150,000 after purchasing an additional 148,360 shares in the last quarter. Finally, NewSquare Capital LLC increased its stake in Eli Lilly and by 5.5% in the second quarter. NewSquare Capital LLC now owns 13,376 shares of the company’s stock valued at $1,101,000 after purchasing an additional 702 shares in the last quarter. Institutional investors and hedge funds own 76.45% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.